Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Blueprint Medicines Corp shares valued at $340,033 were sold by Carter Percy H. on Jun 03 ’25. At $127.88 per share, Carter Percy H. sold 2,659 shares. The insider’s holdings dropped to 54,206 shares worth approximately $6.95 million following the completion of this transaction.
Also, Albers Jeffrey W. sold 5,000 shares, netting a total of over 505,692 in proceeds. Following the sale of shares at $101.14 each, the insider now holds 146,630 shares.
Before that, Albers Jeffrey W. had added 5,000 shares to its account. In a trade valued at $505,686, the Director bought Blueprint Medicines Corp shares for $101.14 each.
As published in a research note from Wedbush on June 02, 2025, Blueprint Medicines Corp [BPMC] has been rated down from an Outperform to a Neutral and the price target has been revised to $129. As of March 18, 2025, Wolfe Research has initiated its “an Outperform” rating for BPMC. Earlier on March 17, 2025, Jefferies initiated its rating. Their recommendation was “a Buy” for BPMC stock.
Analyzing BPMC Stock Performance
On last trading session,, Blueprint Medicines Corp [NASDAQ: BPMC] plunged -0.08% to $128.15. The stock’s lowest price that day was $128.1, but it reached a high of $128.31 in the same session. During the last five days, there has been a surge of approximately 0.02%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 20.78%. Shares of the company reached a 52-week high of $128.45 on 06/23/25 and a 52-week low of $73.04 on 04/09/25.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 128.06, which, if violated, would cause prices to drop to 127.98. In the upper region, resistance lies at 128.27. The next price resistance is at 128.40. RSI (Relative Strength Index) is 74.85 on the 14-day chart, showing overbought technical sentiment.
Is Blueprint Medicines Corp subject to short interest?
Stocks of Blueprint Medicines Corp saw a sharp steep in short interest on 2025-06-13 dropping by -2.54 million shares to 3.13 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 5.67 million shares. A decline of -81.11% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.62 of the overall float, the days-to-cover ratio (short ratio) decline to 0.62.
Which companies own the most shares of Blueprint Medicines Corp (BPMC)?
In terms of Blueprint Medicines Corp share price expectations, FactSet research, analysts set an average price target of 141 in the next 12 months, up nearly 9.94% from the previous closing price of $128.25. Analysts anticipate Blueprint Medicines Corp stock to reach 150 by 2025, with the lowest price target being 132. In spite of this, 10 analysts ranked Blueprint Medicines Corp stock as Buy at the end of 2025. On March 07, 2025, Scotiabank assigned a price target of “a Sector outperform” to the stock and initiated coverage with a $150.
